Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.bsky.social
Official Account of the National Cancer Institute Acquired Resistance to Therapy Network (ARTNet).
https://www.nciartnet.org/
https://www.nciartnet.org/
Pinned
The Acquired Resistance to Therapy Network
nciartnet.org
The Acquired Resistance to Therapy Network (ARTNet), of
the National Cancer Institute, focuses on mechanisms of acquired resistance to cancer therapies & disease recurrence and integrates those findings through team science. Learn more at nciartnet.org and www.cancer.gov/about-nci/or...
the National Cancer Institute, focuses on mechanisms of acquired resistance to cancer therapies & disease recurrence and integrates those findings through team science. Learn more at nciartnet.org and www.cancer.gov/about-nci/or...
At today's #ARTNetSCMeeting, Dr. Sohail Tavazoie of
@rockefeller.edu presented his research on the regulation of #metastasis.
@rockefeller.edu presented his research on the regulation of #metastasis.
November 13, 2025 at 8:55 PM
At today's #ARTNetSCMeeting, Dr. Sohail Tavazoie of
@rockefeller.edu presented his research on the regulation of #metastasis.
@rockefeller.edu presented his research on the regulation of #metastasis.
Join SITC and NCI for the Computational Immuno-oncology Webinar Series Course 9: Using Spatial Biology to Monitor Tumor Immune Interactions on Nov. 13, 2025 (1–2 p.m. ET).
Register for this free digital event: sitcancer.org/CompIO
Register for this free digital event: sitcancer.org/CompIO
2025 SITC-NCI Computational Immuno-Oncology Webinar Series | Ten Free Webinars
In partnership with the National Cancer Institute (NCI), SITC is pleased to launch a new series of ten computational immuno-oncology webinars that will focus specifically on advanced methods and clini...
sitcancer.org
November 12, 2025 at 4:58 PM
Join SITC and NCI for the Computational Immuno-oncology Webinar Series Course 9: Using Spatial Biology to Monitor Tumor Immune Interactions on Nov. 13, 2025 (1–2 p.m. ET).
Register for this free digital event: sitcancer.org/CompIO
Register for this free digital event: sitcancer.org/CompIO
Dr. Sandulache is MPI of the #ARTNet H-CARR center 👏👏
This #VeteransDay the NRG Oncology podcast co-hosts sit with NRG Veteran Affairs-Military Treatment Facility Subcommittee Chair Vlad Sandulache to discuss the subcommittee and their goals + clinical research at VA sites. nrgoncology.org/Podcast
This #VeteransDay the NRG Oncology podcast co-hosts sit with NRG Veteran Affairs-Military Treatment Facility Subcommittee Chair Vlad Sandulache to discuss the subcommittee and their goals + clinical research at VA sites. nrgoncology.org/Podcast
November 7, 2025 at 9:04 PM
Dr. Sandulache is MPI of the #ARTNet H-CARR center 👏👏
This #VeteransDay the NRG Oncology podcast co-hosts sit with NRG Veteran Affairs-Military Treatment Facility Subcommittee Chair Vlad Sandulache to discuss the subcommittee and their goals + clinical research at VA sites. nrgoncology.org/Podcast
This #VeteransDay the NRG Oncology podcast co-hosts sit with NRG Veteran Affairs-Military Treatment Facility Subcommittee Chair Vlad Sandulache to discuss the subcommittee and their goals + clinical research at VA sites. nrgoncology.org/Podcast
New paper in Immunity: Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma
t.co/RswnD7TE2s
t.co/RswnD7TE2s
http://dlvr.it/TP1GtT
t.co
November 3, 2025 at 3:08 PM
New paper in Immunity: Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma
t.co/RswnD7TE2s
t.co/RswnD7TE2s
The latest issue of the #ARTNet Newsletter is out!
It features highlights and reports from the ARTNet Scientific Retreat held in September 2025, along with updates on network progress and ongoing initiatives. indd.adobe.com/view/9af991c...
It features highlights and reports from the ARTNet Scientific Retreat held in September 2025, along with updates on network progress and ongoing initiatives. indd.adobe.com/view/9af991c...
October 17, 2025 at 5:46 PM
The latest issue of the #ARTNet Newsletter is out!
It features highlights and reports from the ARTNet Scientific Retreat held in September 2025, along with updates on network progress and ongoing initiatives. indd.adobe.com/view/9af991c...
It features highlights and reports from the ARTNet Scientific Retreat held in September 2025, along with updates on network progress and ongoing initiatives. indd.adobe.com/view/9af991c...
ARTNet investigator Dr. Moran Amit of @mdanderson.bsky.social report in Nature that cancer cells can damage protective nerve coverings, causing nerve injury and chronic inflammation.These injuries drive immune exhaustion and immunotherapy resistance.
tinyurl.com/y3pk453e
tinyurl.com/y3pk453e
Cancer-associated nerve injury leads to chronic inflammation and immunotherapy resistance
Cancer-associated nerve injury leads to chronic inflammation and immunotherapy resistance
tinyurl.com
October 14, 2025 at 5:18 PM
ARTNet investigator Dr. Moran Amit of @mdanderson.bsky.social report in Nature that cancer cells can damage protective nerve coverings, causing nerve injury and chronic inflammation.These injuries drive immune exhaustion and immunotherapy resistance.
tinyurl.com/y3pk453e
tinyurl.com/y3pk453e
At today’s Scientific Exchange Meeting, Co-chair Dr. Alan Hutson of @roswellpark.bsky.social shared network updates and welcomed new WG Chairs Drs. Herve Tiriac & Mark Long.
Dr. Victoria Seewalt of @cityofhope.bsky.social presented on pregnancy-associated BrCa: TME & field effect. #ARTNetSC
Dr. Victoria Seewalt of @cityofhope.bsky.social presented on pregnancy-associated BrCa: TME & field effect. #ARTNetSC
October 9, 2025 at 7:20 PM
At today’s Scientific Exchange Meeting, Co-chair Dr. Alan Hutson of @roswellpark.bsky.social shared network updates and welcomed new WG Chairs Drs. Herve Tiriac & Mark Long.
Dr. Victoria Seewalt of @cityofhope.bsky.social presented on pregnancy-associated BrCa: TME & field effect. #ARTNetSC
Dr. Victoria Seewalt of @cityofhope.bsky.social presented on pregnancy-associated BrCa: TME & field effect. #ARTNetSC
New study in reveals that ARID1A mutations drive resistance to osimertinib in EGFR-mutant NSCLC.Dual inhibition of EGFR + WEE1 overcomes resistance and suppresses tumor growth in models.ARID1A may serve as a key biomarker & therapeutic target. #ARTNetPublication
pubmed.ncbi.nlm.nih.gov/40518016/
pubmed.ncbi.nlm.nih.gov/40518016/
Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer - PubMed
These findings suggest that ARID1A mutations are critical biomarkers for osimertinib resistance and highlight WEE1 inhibition as a promising therapeutic approach for ARID1A-mutant osimertinib-resistan...
pubmed.ncbi.nlm.nih.gov
October 6, 2025 at 2:21 PM
New study in reveals that ARID1A mutations drive resistance to osimertinib in EGFR-mutant NSCLC.Dual inhibition of EGFR + WEE1 overcomes resistance and suppresses tumor growth in models.ARID1A may serve as a key biomarker & therapeutic target. #ARTNetPublication
pubmed.ncbi.nlm.nih.gov/40518016/
pubmed.ncbi.nlm.nih.gov/40518016/
We are pleased to welcome Dr. Herve Tiriac from UC SanDiego
as the new vice chair of the ARTNet Inflammatory Microenvironment & Tumor Cross Talk Working Group.
as the new vice chair of the ARTNet Inflammatory Microenvironment & Tumor Cross Talk Working Group.
September 19, 2025 at 6:26 PM
We are pleased to welcome Dr. Herve Tiriac from UC SanDiego
as the new vice chair of the ARTNet Inflammatory Microenvironment & Tumor Cross Talk Working Group.
as the new vice chair of the ARTNet Inflammatory Microenvironment & Tumor Cross Talk Working Group.
Congratulations to Dr. Mark Long from the ARTNet CDMC U24
@roswellpark.bsky.social on being elected co-chair of the Functional Screens & Assay Development WG!
The WG is working on leveraging high-throughput methods to understand and combat acquired resistance to therapeutics.
@roswellpark.bsky.social on being elected co-chair of the Functional Screens & Assay Development WG!
The WG is working on leveraging high-throughput methods to understand and combat acquired resistance to therapeutics.
September 16, 2025 at 7:40 PM
Congratulations to Dr. Mark Long from the ARTNet CDMC U24
@roswellpark.bsky.social on being elected co-chair of the Functional Screens & Assay Development WG!
The WG is working on leveraging high-throughput methods to understand and combat acquired resistance to therapeutics.
@roswellpark.bsky.social on being elected co-chair of the Functional Screens & Assay Development WG!
The WG is working on leveraging high-throughput methods to understand and combat acquired resistance to therapeutics.
Panel Discussion # 2 focused on ARTNet's collaborative approach to translating resistance biology into therapheutic strategies.
#ARTNetScientificRetreat2025
#ARTNetScientificRetreat2025
September 12, 2025 at 3:59 PM
Panel Discussion # 2 focused on ARTNet's collaborative approach to translating resistance biology into therapheutic strategies.
#ARTNetScientificRetreat2025
#ARTNetScientificRetreat2025
Cell States, Metabolism and Inflammatory Microenvironment WG shared updates on spatial multi-omics projects tackling therapy resistance in lung, pancreatic & breast cancers, and a joint white paper with PSRC.
#ARTNetScientificRetreat2025
#ARTNetScientificRetreat2025
September 12, 2025 at 2:58 PM
Cell States, Metabolism and Inflammatory Microenvironment WG shared updates on spatial multi-omics projects tackling therapy resistance in lung, pancreatic & breast cancers, and a joint white paper with PSRC.
#ARTNetScientificRetreat2025
#ARTNetScientificRetreat2025
Dr. Seth Gammon presented updates from the Functional Screens&Assay Development WG. Highlights included a new white paper on targeting acquired resistance, a pilot grant on novel screening & collaborative efforts to uncover shared drug vulnerabilities.
#ARTNetScientificRetreat2025
#ARTNetScientificRetreat2025
September 12, 2025 at 2:56 PM
Dr. Seth Gammon presented updates from the Functional Screens&Assay Development WG. Highlights included a new white paper on targeting acquired resistance, a pilot grant on novel screening & collaborative efforts to uncover shared drug vulnerabilities.
#ARTNetScientificRetreat2025
#ARTNetScientificRetreat2025
Dr. Alan Hutson shared updates from the ARTNet CDMC U24
@roswellpark.bsky.social, featuring new resource-sharing catalogs, collaborative research initiatives, and AI-driven tools to enhance cancer research and foster cross-network collaboration.
#ARTNetScientificRetreat2025
@roswellpark.bsky.social, featuring new resource-sharing catalogs, collaborative research initiatives, and AI-driven tools to enhance cancer research and foster cross-network collaboration.
#ARTNetScientificRetreat2025
September 12, 2025 at 2:51 PM
Dr. Alan Hutson shared updates from the ARTNet CDMC U24
@roswellpark.bsky.social, featuring new resource-sharing catalogs, collaborative research initiatives, and AI-driven tools to enhance cancer research and foster cross-network collaboration.
#ARTNetScientificRetreat2025
@roswellpark.bsky.social, featuring new resource-sharing catalogs, collaborative research initiatives, and AI-driven tools to enhance cancer research and foster cross-network collaboration.
#ARTNetScientificRetreat2025
#ARTNetScientificRetreat2025 Poster Session
September 11, 2025 at 9:43 PM
#ARTNetScientificRetreat2025 Poster Session
Flash Talks for Poster Presenters featured research with translational potential:
Katherine Dempsey from PCAC U54 explored SAT1 & CAF polarization in pancreatic cancer.
#ARTNetScientificRetreat2025
Katherine Dempsey from PCAC U54 explored SAT1 & CAF polarization in pancreatic cancer.
#ARTNetScientificRetreat2025
September 11, 2025 at 9:42 PM
Flash Talks for Poster Presenters featured research with translational potential:
Katherine Dempsey from PCAC U54 explored SAT1 & CAF polarization in pancreatic cancer.
#ARTNetScientificRetreat2025
Katherine Dempsey from PCAC U54 explored SAT1 & CAF polarization in pancreatic cancer.
#ARTNetScientificRetreat2025
#ESITalk: Dr.Vincent Bernard (ARTI U54)
@mdanderson.bsky.social revealed how spatial profiling uncovers persister cell populations and immune reshaping after radiation in pancreatic cancer. Targeting KRAS and ferroptosis/cuproptosis defenses may improve radiosensitivity
#ARTNetScientificRetreat2025
@mdanderson.bsky.social revealed how spatial profiling uncovers persister cell populations and immune reshaping after radiation in pancreatic cancer. Targeting KRAS and ferroptosis/cuproptosis defenses may improve radiosensitivity
#ARTNetScientificRetreat2025
September 11, 2025 at 8:47 PM
#ESITalk: Dr.Vincent Bernard (ARTI U54)
@mdanderson.bsky.social revealed how spatial profiling uncovers persister cell populations and immune reshaping after radiation in pancreatic cancer. Targeting KRAS and ferroptosis/cuproptosis defenses may improve radiosensitivity
#ARTNetScientificRetreat2025
@mdanderson.bsky.social revealed how spatial profiling uncovers persister cell populations and immune reshaping after radiation in pancreatic cancer. Targeting KRAS and ferroptosis/cuproptosis defenses may improve radiosensitivity
#ARTNetScientificRetreat2025
#ECITalks: Melissa Stewart from AML U54 @ohsuknight.bsky.social shared how combining venetoclax with the CDK4/6 inhibitor palbociclib overcomes resistance in RAS-mutant AML, reducing tumor burden, improving survival, and reshaping protein synthesis pathways.
#ARTNetScientificRetreat2025
#ARTNetScientificRetreat2025
September 11, 2025 at 8:31 PM
#ECITalks: Melissa Stewart from AML U54 @ohsuknight.bsky.social shared how combining venetoclax with the CDK4/6 inhibitor palbociclib overcomes resistance in RAS-mutant AML, reducing tumor burden, improving survival, and reshaping protein synthesis pathways.
#ARTNetScientificRetreat2025
#ARTNetScientificRetreat2025
#ECITalk: Dr. Moran Amit from H-CARR U54 at @mdanderson.bsky.social shared how tumor-associated nerves drive cancer progression, #metastasis, and therapy resistance. Targeting the neural-tumor microenvironment opens new paths for cancer treatment and #immunotherapy.
#ARTNetScientificRetreat2025
#ARTNetScientificRetreat2025
September 11, 2025 at 8:12 PM
#ECITalk: Dr. Moran Amit from H-CARR U54 at @mdanderson.bsky.social shared how tumor-associated nerves drive cancer progression, #metastasis, and therapy resistance. Targeting the neural-tumor microenvironment opens new paths for cancer treatment and #immunotherapy.
#ARTNetScientificRetreat2025
#ARTNetScientificRetreat2025
#ECITalk: Dr. Surendra Shukla from ARTNet PCAC U54 shared how BACH1 drives pancreatic cancer progression and FOLFIRINOX resistance. Targeting BACH1, directly or with hemin, enhances therapy efficacy and reveals PDIA6 as a key player in unfolded protein response.
#ARTNetScientificRetreat2025
#ARTNetScientificRetreat2025
September 11, 2025 at 7:53 PM
#ECITalk: Dr. Surendra Shukla from ARTNet PCAC U54 shared how BACH1 drives pancreatic cancer progression and FOLFIRINOX resistance. Targeting BACH1, directly or with hemin, enhances therapy efficacy and reveals PDIA6 as a key player in unfolded protein response.
#ARTNetScientificRetreat2025
#ARTNetScientificRetreat2025
Dr. Trever Bivona from BAATAAR-UP center shared findings of how tumor lineages adapt to targeted therapy in EGFR-mutant #lungcancer. Combination strategies such as osimertinib+sonidegib can overcome resistance driven by transcriptional plasticity
tinyurl.com/43d6sma4
#ARTNetScientificRetreat2025
tinyurl.com/43d6sma4
#ARTNetScientificRetreat2025
September 11, 2025 at 7:23 PM
Dr. Trever Bivona from BAATAAR-UP center shared findings of how tumor lineages adapt to targeted therapy in EGFR-mutant #lungcancer. Combination strategies such as osimertinib+sonidegib can overcome resistance driven by transcriptional plasticity
tinyurl.com/43d6sma4
#ARTNetScientificRetreat2025
tinyurl.com/43d6sma4
#ARTNetScientificRetreat2025
Dr. Jeffrey Tyner (ARTNet AML center) highlighted how AML cell differentiation states govern therapy response & resistance. His team developed Myelo-ID, a rapid gene expression test that predicts outcomes & helps guide treatment decisions.
Read more: tinyurl.com/kpt3483z
#ARTNetScientificRetreat2025
Read more: tinyurl.com/kpt3483z
#ARTNetScientificRetreat2025
September 11, 2025 at 6:47 PM
Dr. Jeffrey Tyner (ARTNet AML center) highlighted how AML cell differentiation states govern therapy response & resistance. His team developed Myelo-ID, a rapid gene expression test that predicts outcomes & helps guide treatment decisions.
Read more: tinyurl.com/kpt3483z
#ARTNetScientificRetreat2025
Read more: tinyurl.com/kpt3483z
#ARTNetScientificRetreat2025
Dr. Jeffrey Myers shared advances in overcoming cisplatin resistance in head & neck cancer, highlighting NRF2-driven resistance, immune suppression, and novel biomarkers like HP-MRI and exosomal miRNAs for precision therapy.
More info: nciartnet.org/en/members/h...
#ARTNetScientificRetreat2025
More info: nciartnet.org/en/members/h...
#ARTNetScientificRetreat2025
September 11, 2025 at 5:06 PM
Dr. Jeffrey Myers shared advances in overcoming cisplatin resistance in head & neck cancer, highlighting NRF2-driven resistance, immune suppression, and novel biomarkers like HP-MRI and exosomal miRNAs for precision therapy.
More info: nciartnet.org/en/members/h...
#ARTNetScientificRetreat2025
More info: nciartnet.org/en/members/h...
#ARTNetScientificRetreat2025
Dr. Pankaj Singh shared updates from the Pancreatic Cancer ARTNet Center (PCAC), highlighting metabolic drivers of resistance, MUC1-mediated exosome signaling, and targeting Cyclin K to overcome therapy resistance
More on ARTNet PCAC center:
nciartnet.org/en/members/p...
#ARTNetScientificRetreat2025
More on ARTNet PCAC center:
nciartnet.org/en/members/p...
#ARTNetScientificRetreat2025
September 11, 2025 at 4:40 PM
Dr. Pankaj Singh shared updates from the Pancreatic Cancer ARTNet Center (PCAC), highlighting metabolic drivers of resistance, MUC1-mediated exosome signaling, and targeting Cyclin K to overcome therapy resistance
More on ARTNet PCAC center:
nciartnet.org/en/members/p...
#ARTNetScientificRetreat2025
More on ARTNet PCAC center:
nciartnet.org/en/members/p...
#ARTNetScientificRetreat2025
Drs. Boyi Gan & Dadi Jiang from MD Anderson shared advances from the ARTI Center, exploring ferroptosis&other cell death pathways to overcome tumor radioresistance, highlighting CRIP1-PP2A-MTF1 signaling & therapeutic strategies targeting cuproptosis.
More on ARTI center: tinyurl.com/y85z5yua
More on ARTI center: tinyurl.com/y85z5yua
September 11, 2025 at 4:25 PM
Drs. Boyi Gan & Dadi Jiang from MD Anderson shared advances from the ARTI Center, exploring ferroptosis&other cell death pathways to overcome tumor radioresistance, highlighting CRIP1-PP2A-MTF1 signaling & therapeutic strategies targeting cuproptosis.
More on ARTI center: tinyurl.com/y85z5yua
More on ARTI center: tinyurl.com/y85z5yua